Integrated Filing — IndAS



General information about company

Scrip Code 500257
NSE Symbol LUPIN
MSEI Symbol NOTLISTED
ISIN INE326A01037
Name of company Lupin Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 03-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 19-10-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 03-11-2026   19:30:00
End date and time of board meeting 04-11-2026   00:25:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 7,82,726.00 16,10,415.00
Other income 12,679.00 25,711.00
Total income 7,95,405.00 16,36,126.00
2 Expenses
(a) Cost of materials consumed 1,31,074.00 2,62,240.00
(b) Purchases of stock-in-trade 73,318.00 1,57,545.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (3,578.00) (10,047.00)
(d) Employee benefit expense 1,42,358.00 2,80,658.00
(e) Finance costs 10,571.00 21,535.00
(f) Depreciation, depletion and amortisation expense 48,590.00 93,875.00
(f) Other Expenses
1 Other expenses 2,43,814.00 4,77,934.00
2 Net (gain) / loss on foreign currency transactions (8,701.00) (7,311.00)
Total other expenses 2,35,113.00 4,70,623.00
Total expenses 6,37,446.00 12,76,429.00
3 Total profit before exceptional items and tax 1,57,959.00 3,59,697.00
4 Exceptional items 0.00 0.00
5 Total profit before tax 1,57,959.00 3,59,697.00
6 Tax expense
7 Current tax 7,212.00 1,05,651.00
8 Deferred tax 35,218.00 (3,183.00)
9 Total tax expenses 42,430.00 1,02,468.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 1,15,529.00 2,57,229.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 1.00 (1.00)
16 Total profit (loss) for period 1,15,530.00 2,57,228.00
17 Other comprehensive income net of taxes 3,035.00 6,586.00
18 Total Comprehensive Income for the period 1,18,565.00 2,63,814.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 1,15,526.00 2,57,026.00
Total profit or loss, attributable to non-controlling interests 4.00 202.00
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 1,18,562.00 2,63,675.00
Total comprehensive income for the period attributable to owners of parent non-controlling interests 3.00 139.00
21 Details of equity share capital
Paid-up equity share capital 9,146.00 9,146.00
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 25.27 56.21
Diluted earnings (loss) per share from continuing operations 25.14 55.92
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 25.27 56.21
Diluted earnings (loss) per share from continuing and discontinued operations 25.14 55.92
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes accompanying to the consolidated financial results. 1. The above Consolidated Financial Results were reviewed by the Audit Committee on November 02, 2026 and thereafter approved and taken on record by the Board of Directors at their meeting held on November 03, 2026. The Statutory Auditors of the Company have carried out limited review of the above Consolidated Financial Results pursuant to Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. 2. The Consolidated Financial Results are prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended. 3. The Consolidated Financial Results include the financial results of the subsidiaries, Lupin Pharmaceuticals, Inc. - U.S.A., Lupin Australia Pty Limited - Australia, Nanomi B.V. - Netherlands, Pharma Dynamics (Proprietary) Limited - South Africa, Hormosan Pharma GmbH - Germany, Multicare Pharmaceuticals Philippines Inc. - Philippines, Lupin Atlantis Holdings SA - Switzerland, Lupin Healthcare (UK) Limited - U.K., Lupin Pharma Canada Limited - Canada, Generic Health Pty Limited - Australia, Lupin Mexico S.A. de C.V. - Mexico, Lupin Philippines Inc. - Philippines, Lupin Diagnostics Limited - India, Generic Health SDN. BHD. - Malaysia, Lupin Inc. - U.S.A., Laboratorios Grin S.A. de C.V. - Mexico, Medquimica Industria Farmaceutica LTDA - Brazil, Novel Laboratories, Inc.- U.S.A., Lupin Research Inc. - U.S.A., Lupin Management Inc. - U.S.A, Lupin Europe GmbH - Germany, Lupin Biologics Limited - India, Lupin Oncology Inc. - U.S.A., Lupin Digital Health Limited - India, Avenue Coral Springs LLC - U.S.A., Southern Cross Pharma Pty Ltd - Australia, Lupin Life Sciences Limited - India, Lupin Manufacturing Solutions Limited - India, Medisol S.A.S. - France, Lupin Lanka (Private) Ltd. - Sri Lanka, Lupin NZ Ltd. - New Zealand, Lupinlife Consumer Healthcare Limited - India, Renascience Pharma Limited - U.K., VISUfarma B.V. - Netherlands (w.e.f. April 01, 2026), VISUfarma UK Limited - U.K. (w.e.f. April 01, 2026), VISUfarma SPA - Italy (w.e.f. April 01, 2026), IRIS Bidco SAS - France (w.e.f. April 01, 2026), IRIS BidCo Srl - Italy (w.e.f. April 01, 2026), VISUfarma Espana SL - Spain (w.e.f. April 01, 2026), Laboratorios Nicox SLU - Spain (w.e.f. April 01, 2026), Lupin (Thailand) Limited - Thailand (w.e.f. April 17, 2026), Kaveri Therapeutics, Inc., U.S.A. (w.e.f. July 20, 2026) & joint venture, YL Biologics Limited - Japan. 4. During the quarter ended September 30, 2026, 57,436 (year to date 110,861) equity shares of Rs. 2/- each, fully paid-up, were allotted upon exercise of the vested stock options pursuant to the Lupin Employees Stock Option Plans (ESOPs), resulting in an increase in the paid-up equity share capital by Rs. 0.1 million (year to date Rs. 0.2 million) and securities premium account by Rs. 87.1 million (year to date Rs. 164.0 million). 5. As approved by the Members of the Company at the 44th Annual General Meeting held on August 04, 2026, the Company has disbursed on August 06, 2026 a final dividend of Rs. 18/- per equity share of the face value of Rs. 2/- each aggregating Rs. 8,230.2 million. 6. Effective April 01, 2026, Nanomi B.V., Netherlands, a wholly owned subsidiary has acquired the entire share capital of VISUfarma B.V., Netherlands for a total consideration of Rs. 20,902.7 million (Euro 192.8 million). Fair value of intangibles acquired Rs.16,730.2 million, deferred tax liability Rs. 4,182.5 million, Goodwill Rs. 6,549.4 million has been provisionally accounted based on report of independent valuer. The acquisition related costs are accounted in Other expenses. 7. Effective July 01, 2026, Nanomi B.V., Netherlands, increased its ownership interest in Multicare Pharmaceuticals Philippines Inc. (MPPI) from 56.28% to 99.89% through the acquisition of shares from certain existing shareholders for a consideration amounting to Rs. 3,701.2 million and a share buyback amounting to Rs. 17.0 million. 8. Effective July 20, 2026, the Company through its wholly owned step-down subsidiary, Lupin Inc., U.S.A., sublicensed two intellectual property assets to Kaveri Therapeutics Inc., U.S.A. (Kaveri) in exchange for equity shares valued at Rs. 153.3 million (USD 1.6 million), resulting in an 82.17% ownership interest. Consequently, Lupin Inc. obtained control over Kaveri, and Kaveri is accounted for as a subsidiary. 9. Effective April 02, 2025, the Company through its wholly owned step-down subsidiary, Lupin Healthcare (UK) Limited, U.K., acquired 100% equity share capital of Renascience Pharma Limited, U.K., for a consideration of Rs. 1,361.6 million (GBP 12.3 million). Fair value of intangibles acquired Rs. 1,239.4 million, deferred tax liability Rs. 309.8 million, Goodwill Rs. 325.9 million has been accounted based on report of independent valuer. 10. During the quarter ended September 30, 2026 and year ended March 31, 2026, the Group has recognised an impairment charge of Rs. 246.8 million and Rs. 1,130.1 million respectively related to certain capital work-in-progress, intangible assets and intangible assets under development. 11. Exceptional items a. The Group is exposed to multiple civil lawsuits alleging anticompetitive behavior related to certain products and possible violation of federal and state antitrust laws. These lawsuits were combined into the collection of similar cases referred to as In Re Generic Pharmaceuticals Antitrust Litigation. Such litigation are often resolved through settlement agreements. During the quarter ended March 31, 2026; the Group has based on best estimate, created a provision, of Rs. 1,323.1 million (USD 15.8 million), resulting in cumulative provision of Rs. 5,816.9 million (USD 65.8 million) at year ended March 31, 2026 related to antitrust litigation matters. During the six months ended September 30, 2026, Lupin Pharmaceuticals, Inc., U.S.A., a wholly owned subsidiary of the Group, settled one of the ongoing antitrust matters for an amount of Rs. 3,162.8 million (USD 35.8 million) without admission of liability or wrongdoing. The remaining provision continues to be carried by the Group towards future settlements related to similar cases. b. On February 09, 2026, Lupin Limited and its subsidiary entered into a settlement agreement with Astellas towards ongoing dispute related to Mirabegron ER Tablets a generic version of Myrbetriq ER Tablets in US markets. In respect of the same, Lupin Pharmaceuticals, Inc., U.S.A. paid Rs. 8,475.5 million (USD 90.0 million), which includes Rs. 7,110.8 million (USD 75.0 million) as Prepaid Option and Rs. 1,364.7 million (USD 15.0 million) as one-time payment towards the settlement. During the year ended March 31, 2026, the Group has expensed out Rs. 1,364.7 million (USD 15.0 million) and has capitalised the balance amount towards Prepaid Option. c. The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the New Labour Codes). The New Labour Codes are effective from November 21, 2025 and introduce changes that include, among other things, setting a uniform definition of wages. The Group has assessed the implications of the New Labour Codes and has recognized an incremental cost of Rs. 512.2 million during the year ended March 31, 2026. d. During the year ended March 31, 2026, the Group entered into a settlement agreement with an income of Rs. 873.7 million (USD 10.0 million). e. During the year ended March 31, 2026, the Group has received an arbitration award, consequently accounted an income of Rs. 603.2 million (USD 6.9 million) and a reversal of expense provision of Rs. 611.6 million (USD 7.0 million).



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 5,39,076.00
Capital work-in-progress 93,121.00
Investment property 0.00
Goodwill 3,36,799.00
Other intangible assets 4,17,629.00
Intangible assets under development 39,707.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 2,979.00
Non-current financial assets
Non-current investments 28,126.00
Trade receivables, non-current 0.00
Loans, non-current 343.00
Other non-current financial assets
1 Other Non-Current Financial Assets 1,43,567.00
Total of other non-current financial assets 1,43,567.00
Total non-current financial assets 1,72,036.00
Deferred tax assets (net) 55,693.00
Other non-current assets
1 Non-Current Tax Assets 4,455.00
2 Other Non-Current Assets 22,593.00
Total of other non-current assets 27,048.00
Total non-current assets 16,84,088.00
2 Current assets
Inventories 6,56,252.00
Current financial asset
Current investments 4,14,544.00
Trade receivables, current 6,65,603.00
Cash and cash equivalents 1,93,907.00
Bank balance other than cash and cash equivalents 1,45,849.00
Loans, current 406.00
Other current financial assets
Total of other current financial assets 31,025.00
Total current financial assets 14,51,334.00
Current tax assets (net) 3,336.00
Other current assets
1 Other Current Assets 1,96,094.00
Total of other current assets 1,96,094.00
Total current assets 23,07,016.00
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 39,91,104.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 9,146.00
Other equity 23,95,900.00
Total equity attributable to owners of parent 24,05,046.00
Non controlling interest 69.00
Total equity 24,05,115.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 1,34,159.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Lease Liabilities 43,908.00
2 Other Non-Current Financial Liabilities 5,972.00
Total of other non-current financial liabilities 49,880.00
Total non-current financial liabilities 1,84,039.00
Provisions, non-current 59,205.00
Deferred tax liabilities (net) 62,226.00
Deferred government grants, Non-current 0.00
Other non-current liabilities
1 Other Non-Current Liabilities 26,393.00
Total of other non-current liabilities 26,393.00
Total non-current liabilities 3,31,863.00
Current liabilities
Current financial liabilities
Borrowings, current 4,15,421.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 14,982.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 4,40,822.00
Total Trade payable 4,55,804.00
Other current financial liabilities
1 Lease Liabilities 24,556.00
2 Other Current Financial Liabilities 65,742.00
Total of other current financial liabilities 90,298.00
Total current financial liabilities 9,61,523.00
Other current liabilities 1,77,110.00
1 Other Current Liabilities 1,77,110.00
Total of other current liabilities 1,77,110.00
Provisions, current 53,675.00
Current tax liabilities (Net) 61,818.00
Deferred government grants, Current 0.00
Total current liabilities 12,54,126.00
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 15,85,989.00
Total equity and liabilites 39,91,104.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 a) Pharmaceuticals 7,77,563.00 16,00,998.00
2 b) Others 5,212.00 9,515.00
3 Less: Inter segment 0.00 0.00
Total Segment Revenue 7,82,775.00 16,10,513.00
Less: Inter segment revenue 49.00 98.00
Revenue from operations 7,82,726.00 16,10,415.00
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 a) Pharmaceuticals 1,61,384.00 3,67,440.00
2 b) Others (3,424.00) (7,744.00)
3 Less: Inter segment 0.00 0.00
Total Profit before tax 1,57,960.00 3,59,696.00
i. Finance cost 0.00 0.00
ii. Other Unallocable Expenditure net off Unallocable income 0.00 0.00
Profit before tax 1,57,960.00 3,59,696.00
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 a) Pharmaceuticals 39,72,872.00 39,72,872.00
2 b) Others 23,473.00 23,473.00
3 Less: Inter segment (5,241.00) (5,241.00)
Total Segment Asset 39,91,104.00 39,91,104.00
Un-allocable Assets 0.00 0.00
Net Segment Asset 39,91,104.00 39,91,104.00
4 Segment Liabilities
Segment Liabilities
1 a) Pharmaceuticals 15,75,604.00 15,75,604.00
2 b) Others 15,622.00 15,622.00
3 Less: Inter segment (5,237.00) (5,237.00)
Total Segment Liabilities 15,85,989.00 15,85,989.00
Un-allocable Liabilities 0.00 0.00
Net Segment Liabilities 15,85,989.00 15,85,989.00
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified subsequently to profit or loss (423.00) (431.00)
Total Amount of items that will not be reclassified to profit and loss (423.00) (431.00)
2 Income tax relating to items that will not be reclassified to profit or loss (143.00) (154.00)
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified subsequently to profit or loss 3,535.00 8,752.00
Total Amount of items that will be reclassified to profit and loss 3,535.00 8,752.00
4 Income tax relating to items that will be reclassified to profit or loss 220.00 1,889.00
5 Total Other comprehensive income 3,035.00 6,586.00



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 3,59,697.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 21,535.00
Adjustments for decrease (increase) in inventories (34,385.00)
Adjustments for decrease (increase) in trade receivables, current (17,619.00)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (39,179.00)
Adjustments for decrease (increase) in other non-current assets (514.00)
Adjustments for other financial assets, non-current (1,040.00)
Adjustments for other financial assets, current 23,931.00
Adjustments for other bank balances (3,971.00)
Adjustments for increase (decrease) in trade payables, current 32,417.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 5,538.00
Adjustments for increase (decrease) in other non-current liabilities 388.00
Adjustments for depreciation and amortisation expense 93,875.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current (7,929.00)
Adjustments for provisions, non-current 3,245.00
Adjustments for other financial liabilities, current (44,299.00)
Adjustments for other financial liabilities, non-current 250.00
Adjustments for unrealised foreign exchange losses gains 25,898.00
Adjustments for dividend income 0.00
Adjustments for interest income 11,776.00
Adjustments for share-based payments 8,267.00
Adjustments for fair value losses (gains) (9,517.00)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow (2,699.00)
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 153.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 42,569.00
Net cash flows from (used in) operations 4,02,266.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 1,11,641.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 2,90,625.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 2,03,973.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 2,340.00
Purchase of property, plant and equipment 69,210.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 11,995.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (59,404.00)
Net cash flows from (used in) investing activities (3,18,252.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 37,182.00
Proceeds from issuing shares 726.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 46,505.00
Payments of lease liabilities 10,370.00
Dividends paid 82,302.00
Interest paid 19,605.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (1,95,238.00)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (2,22,865.00)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents (2,22,865.00)
Cash and cash equivalents cash flow statement at beginning of period 4,16,773.00
Cash and cash equivalents cash flow statement at end of period 1,93,908.00